Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

NCT07262567 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: GFH375
DRUG: Chemotherapy

Sponsor

Genfleet Therapeutics (Shanghai) Inc.